About this study: 

This extension study looks at the long-term safety and effectiveness of remibrutinib in people with CSU(Chronic Spontaneous Uticaria“Hives”   who completed a prior study, while also allowing continued access to the medication after the Phase 3 studies, when appropriate.

Who can join:

• You must sign a consent form before any study procedures.

• You must be 18 years or older.
• You must have completed a previous remibrutinib study.
• You should be willing and able to follow the study visits and instructions.

Who cannot join:

• You have a high risk of bleeding or a bleeding disorder.

• You have a history of stomach or intestinal bleeding.
• You need to take blood thinners or medications that affect clotting.
• You have current or past liver disease.
• You have other serious health conditions (such as heart, lung, kidney, immune, or mental health conditions) that could make participation unsafe or affect study results.

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.